Methylnaltrexone

Actinium Appoints Lynn Bodarky as Chief Business Officer

Retrieved on: 
Friday, November 3, 2023

NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that Lynn Bodarky has been named Chief Business Officer to lead the Company's business development, licensing, and collaboration activities. Ms. Bodarky joins Actinium with over 25 years of proven business development and licensing experience at large global pharmaceutical and innovative biotechnology companies including Pfizer, Merck, Progenics and HiFiBiO. Over her career, she has executed a wide array of business transactions totaling over $5 billion in value across oncology, autoimmune and neurological indications.

Key Points: 
  • NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that Lynn Bodarky has been named Chief Business Officer to lead the Company's business development, licensing, and collaboration activities.
  • Ms. Bodarky joins Actinium with over 25 years of proven business development and licensing experience at large global pharmaceutical and innovative biotechnology companies including Pfizer, Merck, Progenics and HiFiBiO.
  • Ms. Bodarky joins Actinium from HiFiBiO Therapeutics, a clinical-stage biotechnology company developing immunotherapies for oncology and autoimmune diseases, where she was Senior Vice President, Global Head of Business Development & Operations.
  • "I am incredibly excited to join Actinium given the numerous near- and longer-term business development opportunities.

Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty

Retrieved on: 
Thursday, August 3, 2023

HealthCare Royalty (“HCRx”) has acquired the tiered, sales-based royalty rights on worldwide net sales of RELISTOR while Lantheus retains the rights to future sales-based milestone payments.

Key Points: 
  • HealthCare Royalty (“HCRx”) has acquired the tiered, sales-based royalty rights on worldwide net sales of RELISTOR while Lantheus retains the rights to future sales-based milestone payments.
  • “The sale of the RELISTOR royalties unlocks significant value, which can be strategically channeled into our rapidly growing and evolving radiopharmaceutical business.
  • During the twelve-month period ended December 31, 2022, Lantheus reported $22.3 million in aggregate royalties derived from net sales of RELISTOR.
  • Foley Hoag LLP acted as legal advisor to Lantheus and Cadwalader, Wickersham & Taft LLP acted as legal advisor to HCRx in connection with the transaction.

Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide

Retrieved on: 
Tuesday, November 1, 2022

Noramco, LLC, a leading North American producer of controlled substance and specialty bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, today announced it has reactivated its previously filed Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the active pharmaceutical ingredient methylnaltrexone bromide.

Key Points: 
  • Noramco, LLC, a leading North American producer of controlled substance and specialty bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, today announced it has reactivated its previously filed Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the active pharmaceutical ingredient methylnaltrexone bromide.
  • Methylnaltrexone bromide is the active ingredient in Relistor, an FDA-approved prescription medication indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic pain.
  • Methylnaltrexone bromide is a significant advancement, providing relief for these patients who need to manage chronic pain with opioids.
  • Noramco, headquartered in Wilmington, Delaware, is a leading North American producer of controlled substances bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry.

Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data Analysis at the 2021 American Society of Clinical Oncology Annual Meeting and 2021 Annual Meeting of the Multinational Association of Supportive Care in Cancer

Retrieved on: 
Thursday, June 3, 2021

A scientific poster featuring identical data will be presented at the 2021 Annual Meeting of the Multinational Association of Supportive Care in Cancer (MASCC), which will be held virtually June 24-26, 2021.

Key Points: 
  • A scientific poster featuring identical data will be presented at the 2021 Annual Meeting of the Multinational Association of Supportive Care in Cancer (MASCC), which will be held virtually June 24-26, 2021.
  • Monitor for the development of severe, persistent, or worsening abdominal pain; discontinue RELISTOR in patients who develop this symptom.
  • If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their health care provider.
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, and yawning have occurred in patients treated with RELISTOR.

Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting

Retrieved on: 
Friday, May 21, 2021

b'Lantheus Holdings, Inc. (the \xe2\x80\x9cCompany\xe2\x80\x9d) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation featuring data from the Company\xe2\x80\x99s Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) Virtual Meeting, which will be held from June 4-8, 2021.\nThe presentation will be made available for the duration of conference.\nDetails for the ASCO presentation are as follows:\nTitle: PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)\xe2\x80\x94A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.\nLantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow\xc2\xae serious medical conditions.

Key Points: 
  • b'Lantheus Holdings, Inc. (the \xe2\x80\x9cCompany\xe2\x80\x9d) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation featuring data from the Company\xe2\x80\x99s Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) Virtual Meeting, which will be held from June 4-8, 2021.\nThe presentation will be made available for the duration of conference.\nDetails for the ASCO presentation are as follows:\nTitle: PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)\xe2\x80\x94A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.\nLantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow\xc2\xae serious medical conditions.
  • Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY\xc2\xae Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite\xc2\xae (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA\xc2\xae for the treatment of certain rare neuroendocrine tumors; and RELISTOR\xc2\xae for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.
  • The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden.
  • For more information, please visit www.lantheus.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210521005043/en/\n'

$2+ Billion Worldwide Opiod Induced Constipation Drugs Industry to 2028 - Key Drivers, Challenges and Opportunities

Retrieved on: 
Tuesday, February 23, 2021

In patients seeking palliative care, doctors prescribe mu-receptor antagonists and prostaglandin derivatives to cure opioid induced constipation.

Key Points: 
  • In patients seeking palliative care, doctors prescribe mu-receptor antagonists and prostaglandin derivatives to cure opioid induced constipation.
  • The current report also comprehends qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints, and opportunities that give a better market understanding of the overall opioid induced constipation drugs market.
  • Key questions answered in this report:
    What are the current market trends and dynamics in the opioid induced constipation drugs market and valuable opportunities for emerging players?
  • Notable developments going on in the opioid induced constipation drugs market.

Salix's Methylnaltrexone Abstract Wins Best Of Meeting Award At ASRA's Annual Pain Medicine Meeting

Retrieved on: 
Thursday, November 19, 2020

"Salix is honored to be recognized by ASRA for a Best of Meeting Award, a distinction that is reserved for the highest scoring scientific abstracts.

Key Points: 
  • "Salix is honored to be recognized by ASRA for a Best of Meeting Award, a distinction that is reserved for the highest scoring scientific abstracts.
  • Our scientific poster presentation includes analyses examining the effects of subcutaneous methylnaltrexone in cancer and non-cancer patients with opioid-induced constipation,"said Howard Franklin, M.D., chief medical officer, Salix.
  • The Salix abstract will be available via the ASRA online portal beginning Nov. 21:
    Shah, Eric.
  • Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care.

Global Constipation Treatment Market (2020 to 2027) - by Therapeutic, Disease, Distribution Channel and Geography - ResearchAndMarkets.com

Retrieved on: 
Friday, October 30, 2020

The "Constipation Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapeutic; Disease; Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Constipation Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapeutic; Disease; Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.
  • The key factors driving the market growth include the rising prevalence of chronic constipation and increasing number of FDA approvals and drug developments drive the market growth.
  • Based on therapeutic, the constipation treatment market is segmented into laxatives, chloride channel activators, peripherally acting mu-opioid receptor antagonists, GC-C agonists, and 5-HT4 receptor agonists.

Salix Presents Two Methylnaltrexone Scientific Posters At PAINWeek 2020

Retrieved on: 
Friday, September 11, 2020

BRIDGEWATER, N.J., Sept. 11, 2020 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced that two encore methylnaltrexone scientific posters will be presented at PAINWeek Live Virtual Conference , being held Sept. 11-13, 2020.

Key Points: 
  • BRIDGEWATER, N.J., Sept. 11, 2020 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced that two encore methylnaltrexone scientific posters will be presented at PAINWeek Live Virtual Conference , being held Sept. 11-13, 2020.
  • "One of Salix's scientific poster presentations at PAINWeek includes analysis examining the effects of methylnaltrexone on patients with advanced illness who were hospitalized with opioid induced constipation (OIC)," said Howard Franklin, MD, chief medical officer, Salix Pharmaceuticals.
  • "Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation."
  • "Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis."

Salix Announces Two Methylnaltrexone Poster Presentations For Opioid-Induced Constipation At PAINWeek 2019

Retrieved on: 
Tuesday, September 3, 2019

BRIDGEWATER, N.J., Sept. 3, 2019 /PRNewswire/ --Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, will present two posters at PAINWeek 2019, being held in Las Vegas (Sept. 3-7, 2019).

Key Points: 
  • BRIDGEWATER, N.J., Sept. 3, 2019 /PRNewswire/ --Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, will present two posters at PAINWeek 2019, being held in Las Vegas (Sept. 3-7, 2019).
  • The complete list of poster presentations from Salix to be presented on Thursday, Sept. 5, from 6:30 to 8:30 p.m., includes:
    RELISTOR (methylnaltrexone bromide) is a prescription medicine used to treat constipation in adults that is caused by prescription pain medicines called opioids.
  • Do not take RELISTOR if you have a bowel blockage (called an intestinal obstruction) or have a history of bowel blockage.
  • RELISTOR can cause serious side effects such as a tear in your stomach or intestinal wall (perforation).